TARO - Taro Pharmaceutical Is Thriving Against The Generic Drug Apocalypse - Shares Are Undervalued
Introduction
Taro Pharmaceuticals (TARO) is an generic pharmaceutical company achieving over $600+ million in sales in FY2018 stemming from organic volume growth. The company has an unique structure, being located in Israel but is 85% owned by Indian generic company Sun Pharmaceuticals and mostly does business in the United States with over 90%+ of its revenue stream coming from this geographical segment.
TARO arguably has the best financial status amongst comparable peers in the sector due to it having zero debt; impressive prescription volume growth; minor litigation risks; much improved management since 2017;